Olea europaea leaf extract suppress stemness-Characteristics of gastric cancer via long non-coding RNAs

5-Fluorouracil (5-FU) and Cisplatin (Cis) are insufficient to fight against stem-like cancer cell (CSC)-phenotype Gastric cancer (GC). Therefore, new therapeutic approaches are required to treat CSC-GC patients. Although the anticancer effect of Olea europaea leaf extract (OLE) has been described fo...

Full description

Saved in:
Bibliographic Details
Published in:European journal of integrative medicine 2022-01, Vol.49, p.102099, Article 102099
Main Authors: Tekin, Cagla, Ercelik, Melis, Tezcan, Gulcin, Aksoy, Secil Ak, Egeli, Unal, Cecener, Gulsah, Tunca, Berrin
Format: Article
Language:English
Subjects:
Anticancer drug
Gastric cancer
Long non-coding RNAs
Stem-like cancer cell
Tumor sphere
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:5-Fluorouracil (5-FU) and Cisplatin (Cis) are insufficient to fight against stem-like cancer cell (CSC)-phenotype Gastric cancer (GC). Therefore, new therapeutic approaches are required to treat CSC-GC patients. Although the anticancer effect of Olea europaea leaf extract (OLE) has been described for multiple types of cancer, including GC, the potential of OLE to be used as a complementary to 5-FU and Cis to treat CSC-GC remains largely unknown. This study uniquely investigated the potential of OLE to be used as complementary to 5-FU-Cis therapy to alleviate the CSC-mediated aggressiveness of GC. The AGS cells, A GC cell line was treated with OLE-only and its combinations with 5-FU-Cis. Tumor aggressiveness, colony formation, and vascularization were analyzed using tumorsphere and clonogenic assays and ex-vivo analyses. In addition, their effect on the expression of CSC markers, including CD133, OCT4, NANOG, and SOX2 and LncRNA, PVT1, MALAT1, H19, and SNHG16, was investigated using RT-qPCR. OLE-only and involvement of OLE to 5-FU+Cis treatment reduced the size of tumor-spheres (p 
ISSN:1876-3820
1876-3839
DOI:10.1016/j.eujim.2022.102099